- Stocks
- Pharma & Healthcare
- Alivus Life Sciences
Alivus Life Sciences share price
NSE: ALIVUSPharma & HealthcareDrug Manufacturers - Specialty & Generic
Alivus Life Sciences at a glance
Alivus Life Sciences (NSE: ALIVUS) closed at ₹1,252.00 on 21 Oct 2026, down 0.46% on the day. With a market capitalisation of ₹15,367 Cr, it ranks 420th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 27.3× trailing earnings, against a return on equity of 17.2% in FY25. Over the past year the share price has risen 35.1%. Its 52-week range is ₹819.00 (22 Jan 2026) to ₹1,493.80 (31 Aug 2026); the last close is 16.2% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹640 Cr (+6.4% year on year) and net profit ₹160 Cr (+31.7%), on a standalone basis. Promoters held 74.87% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹15,367 CrRank 420 on NSE
- P/E (trailing)
- 27.3×
- Price to book
- 4.7×FY25
- EPS (TTM)
- ₹49.12to Q1 FY27
- ROE
- 17.2%FY25
- ROCE
- 22.3%FY25
- Debt to equity
- 0FY25
- Net profit margin
- 20.3%FY25
- Book value / share
- ₹229.92FY25
- 52-week high
- ₹1,493.8031 Aug 2026
- 52-week low
- ₹819.0022 Jan 2026
- 1-year return
- +35.1%
- RSI (14-day)
- 31
Returns to 21 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.46% | −6.9% | −12.4% | +9.4% | +35.1% |
Alivus Life Sciences quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹507 Cr | ₹642 Cr | ₹650 Cr | ₹602 Cr | ₹588 Cr | ₹673 Cr | ₹689 Cr | ₹640 Cr |
| Revenue YoY | −14.9% | +12.1% | +21.0% | +2.2% | +16.0% | +4.8% | +6.1% | +6.4% |
| Net profit | ₹95 Cr | ₹137 Cr | ₹142 Cr | ₹122 Cr | ₹130 Cr | ₹150 Cr | ₹163 Cr | ₹160 Cr |
| Net profit YoY | −19.7% | +15.3% | +44.9% | +9.0% | +36.4% | +9.7% | +14.7% | +31.7% |
| Net margin | 18.8% | 21.3% | 21.8% | 20.2% | 22.1% | 22.3% | 23.6% | 25.0% |
| EPS | ₹7.78 | ₹11.18 | ₹11.57 | ₹9.91 | ₹10.60 | ₹12.25 | ₹13.23 | ₹13.04 |
Alivus Life Sciences financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | ₹1,885 Cr | ₹2,123 Cr | ₹2,161 Cr | ₹2,283 Cr | ₹2,387 Cr |
| Operating profit | ₹471 Cr | ₹565 Cr | ₹629 Cr | ₹631 Cr | ₹654 Cr |
| Net profit | ₹352 Cr | ₹419 Cr | ₹467 Cr | ₹471 Cr | ₹486 Cr |
| EPS (₹) | ₹32.61 | ₹35.63 | ₹38.11 | ₹38.43 | ₹39.63 |
| Cash from operations | ₹388 Cr | ₹598 Cr | ₹313 Cr | ₹414 Cr | ₹392 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹753 Cr | ₹2,054 Cr | ₹2,138 Cr | ₹2,332 Cr | ₹2,817 Cr |
Alivus Life Sciences shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 74.99% | 74.94% | 74.91% | 74.91% | 74.87% | 74.87% |
| Foreign institutions | 6.57% | 6.42% | 6.84% | 5.09% | 5.29% | 5.54% |
| Domestic institutions | 5.19% | 5.61% | 5.47% | 7.12% | 7.28% | 7.18% |
| Non-institutions | 13.25% | 13.03% | 12.78% | 12.88% | 12.56% | 12.41% |
Alivus Life Sciences vs peers
The listed Pharma & Healthcare companies nearest to Alivus Life Sciences by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ONESOURCEOnesource Specialty Pharma | ₹1,371.40 | +0.54% | −25.5% | ₹15,723 Cr | — | −1.3% |
| SYNGENESyngene International | ₹389.35 | −2.42% | −38.5% | ₹15,717 Cr | 49.4 | 6.5% |
| ERISEris Lifesciences | ₹1,129.50 | +1.31% | −29.8% | ₹15,652 Cr | 24.9 | 15.9% |
| APLLTDAlembic Pharmaceuticals | ₹785.00 | −1.75% | −17.2% | ₹15,430 Cr | 22.9 | 11.2% |
| ALIVUSAlivus Life Sciences | ₹1,252.00 | −0.46% | +35.1% | ₹15,367 Cr | 27.3 | 17.2% |
| POLYMEDPoly Medicure | ₹1,502.40 | −3.07% | −19.4% | ₹15,228 Cr | 47.4 | 10.4% |
| ASTRAZENAstraZeneca Pharma India | ₹6,055.50 | −0.30% | −34.3% | ₹15,139 Cr | 80.9 | 15.0% |
Ask anything about Alivus Life Sciences
Pivot answers on the live chart with evidence you can check, and tests strategies against ALIVUS's own history. Try: “Why has ALIVUS moved over the last three months?” · “Backtest a 50-day moving-average crossover on ALIVUS over five years” · “Compare ALIVUS with ONESOURCE on margins and valuation”
Frequently asked questions about Alivus Life Sciences
What is the share price of Alivus Life Sciences today?
Alivus Life Sciences (NSE: ALIVUS) last closed at ₹1,252.00 on 21 Oct 2026. Its 52-week high is ₹1,493.80 and its 52-week low is ₹819.00.
What is the market cap of Alivus Life Sciences?
Alivus Life Sciences' market capitalisation is ₹15,367 Cr (₹15,367 Cr) at the 21 Oct 2026 close, ranking 420th among the NSE companies Pivot tracks.
What is the P/E ratio of Alivus Life Sciences?
Alivus Life Sciences trades at a trailing P/E of 27.3. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 47.4.
What is the ROE and ROCE of Alivus Life Sciences?
Return on equity was 17.2% in FY25 and return on capital employed was 22.3% in FY25 (standalone figures).
Is Alivus Life Sciences a debt-free company?
Alivus Life Sciences is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What were Alivus Life Sciences' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Alivus Life Sciences reported revenue of ₹640 Cr, +6.4% year on year, and net profit of ₹160 Cr, +31.7% year on year.
How has Alivus Life Sciences stock performed over the last year?
Alivus Life Sciences' share price has risen 35.1% over the past year, +9.4% over three months and −12.4% over one month, to the 21 Oct 2026 close.
What is the shareholding pattern of Alivus Life Sciences?
As of 30 Jun 2026: promoters 74.87%, foreign institutions 5.54%, domestic institutions 7.18%, non-institutions 12.41%.
Who are Alivus Life Sciences' competitors?
The listed Pharma & Healthcare companies closest to Alivus Life Sciences by market cap are Onesource Specialty Pharma, Syngene International, Eris Lifesciences, Alembic Pharmaceuticals, Poly Medicure and AstraZeneca Pharma India.
Is Alivus Life Sciences a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Alivus Life Sciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ALIVUS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026 (returns and ratios at the 21 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text